# Controlled Human Malaria Infection Transmission Model - Phase A

> **NCT04280692** · PHASE1,PHASE2 · SUSPENDED · sponsor: **University of Oxford** · enrollment: 44 (actual)

## Conditions studied

- Malaria,Falciparum

## Interventions

- **BIOLOGICAL:** PfSPZ Challenge
- **DRUG:** Sulfadoxine-Pyrimethamine
- **DRUG:** Piperaquine
- **DRUG:** Artemether lumefantrine
- **DRUG:** Primaquine

## Key facts

- **NCT ID:** NCT04280692
- **Lead sponsor:** University of Oxford
- **Sponsor class:** OTHER
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** SUSPENDED
- **Start date:** 2022-08-22
- **Primary completion:** 2025-12
- **Final completion:** 2026-08
- **Target enrollment:** 44 (ACTUAL)
- **Why stopped:** Study halted prematurely due to US FDA clinical hold on PfSPZ Challenge
- **Last updated:** 2024-05-23

## Collaborators

- [object Object]
- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04280692

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04280692, "Controlled Human Malaria Infection Transmission Model - Phase A". Retrieved via AI Analytics 2026-06-01 from https://api.ai-analytics.org/clinical/NCT04280692. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*